Corpus ID: 212454502

Clinical Significance of Serum Biomarker S 100 B to Predict Outcome After Traumatic Brain Injury

@inproceedings{Gahlot2017ClinicalSO,
  title={Clinical Significance of Serum Biomarker S 100 B to Predict Outcome After Traumatic Brain Injury},
  author={G. Gahlot and Y. Soni and G. Joshi and R. Saxena},
  year={2017}
}
  • G. Gahlot, Y. Soni, +1 author R. Saxena
  • Published 2017
  • Background: Traumatic brain injury (TBI) is a common cause of death and disability, worldwide. Early recognition of patients with brain cellular damage allows for early rehabilitation and patient outcome improvement. Serum protein S-100B determinations have been widely suggested the most promising biomarker for TBI. It has been proposed that this marker is useful in a Neurointensive Care Unit (NICU) as a monitoring parameter. The main objective of this study is to assess the value of including… CONTINUE READING

    Tables from this paper

    References

    SHOWING 1-10 OF 29 REFERENCES
    S100B protein may detect brain death development after severe traumatic brain injury.
    • 42
    GFAP and S100B in the acute phase of mild traumatic brain injury
    • 142
    Serum S-100B protein as a molecular marker in severe traumatic brain injury.
    • 84
    The early fall in levels of S-100 beta in traumatic brain injury.
    • 35
    Some prognostic models for traumatic brain injury were not valid.
    • 59